Cargando…
Diagnostic and cost‐effectiveness of axial skeleton MRI in staging high‐risk prostate cancer
INTRODUCTION: Current literature suggests that axial skeleton magnetic resonance imaging (AS‐MRI) is more sensitive than Tc 99m bone scintigraphy (BS) for detecting bone metastases (BM) in high‐risk prostate cancer (PCa). However, BS is still widely performed. Its diagnostic accuracy has been studie...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071081/ https://www.ncbi.nlm.nih.gov/pubmed/37025475 http://dx.doi.org/10.1002/bco2.210 |
_version_ | 1785019125097037824 |
---|---|
author | El‐Taji, Omar Evans, Hannah Arora, Vandan Amin, Suzanne Kumar, Manal Rajan, Thiagarajan Nambi |
author_facet | El‐Taji, Omar Evans, Hannah Arora, Vandan Amin, Suzanne Kumar, Manal Rajan, Thiagarajan Nambi |
author_sort | El‐Taji, Omar |
collection | PubMed |
description | INTRODUCTION: Current literature suggests that axial skeleton magnetic resonance imaging (AS‐MRI) is more sensitive than Tc 99m bone scintigraphy (BS) for detecting bone metastases (BM) in high‐risk prostate cancer (PCa). However, BS is still widely performed. Its diagnostic accuracy has been studied; however, its feasibility and cost implications are yet to be examined. METHODS: We reviewed all patients with high risk PCa undergoing AS‐MRI over a 5‐year period. AS‐MRI was performed on patients with histologically confirmed PCa and either PSA > 20 ng/ml, Gleason ≥8, or TNM Stage ≥T3 or N1 disease. All AS‐MRI studies were obtained using a 1.5‐T AchievaPhilips™MRI scanner. We compared the AS‐MRI positivity and equivocal rate with that of BS. Data were analysed according to Gleason score, T‐stage and PSA. Multivariate logistic regression analyses were used to quantify the strength of association between positive scans and clinical variables. Feasibility and burden of expenditure was also evaluated. RESULTS: Five hundred three patients with a median age of 72 and a mean PSA of 34.8 ng/ml were analysed. Eighty‐eight patients (17.5%) were positive for BM on AS‐MRI (mean PSA 99 [95% CI 69.1–129.9]). Comparatively 409 patients (81.3%) were negative for BM on AS‐MRI (mean PSA 24.7 (95% CI [21.7–27.7]) (p = 0.007); 1.2% (n = 6) of patients had equivocal results (mean PSA 33.4 [95% CI 10.5–56.3]). There was no significant difference in age (p = 0.122) between this group and patients with a positive scan, but there was a significant difference in PSA (p = 0.028), T stage (p = 0.006) and Gleason score (p = 0.023). In comparison with BS, AS‐MRI detection rate was equivalent or higher compared with the literature. Based on NHS tariff calculations, there would be a minimum cost saving of £8406.89. All patients underwent AS‐MRI within 14 days. CONCLUSION: The use of AS‐MRI to stage BM in high‐risk PCa is both feasible and results in a reduced burden of expenditure. |
format | Online Article Text |
id | pubmed-10071081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100710812023-04-05 Diagnostic and cost‐effectiveness of axial skeleton MRI in staging high‐risk prostate cancer El‐Taji, Omar Evans, Hannah Arora, Vandan Amin, Suzanne Kumar, Manal Rajan, Thiagarajan Nambi BJUI Compass Original Articles INTRODUCTION: Current literature suggests that axial skeleton magnetic resonance imaging (AS‐MRI) is more sensitive than Tc 99m bone scintigraphy (BS) for detecting bone metastases (BM) in high‐risk prostate cancer (PCa). However, BS is still widely performed. Its diagnostic accuracy has been studied; however, its feasibility and cost implications are yet to be examined. METHODS: We reviewed all patients with high risk PCa undergoing AS‐MRI over a 5‐year period. AS‐MRI was performed on patients with histologically confirmed PCa and either PSA > 20 ng/ml, Gleason ≥8, or TNM Stage ≥T3 or N1 disease. All AS‐MRI studies were obtained using a 1.5‐T AchievaPhilips™MRI scanner. We compared the AS‐MRI positivity and equivocal rate with that of BS. Data were analysed according to Gleason score, T‐stage and PSA. Multivariate logistic regression analyses were used to quantify the strength of association between positive scans and clinical variables. Feasibility and burden of expenditure was also evaluated. RESULTS: Five hundred three patients with a median age of 72 and a mean PSA of 34.8 ng/ml were analysed. Eighty‐eight patients (17.5%) were positive for BM on AS‐MRI (mean PSA 99 [95% CI 69.1–129.9]). Comparatively 409 patients (81.3%) were negative for BM on AS‐MRI (mean PSA 24.7 (95% CI [21.7–27.7]) (p = 0.007); 1.2% (n = 6) of patients had equivocal results (mean PSA 33.4 [95% CI 10.5–56.3]). There was no significant difference in age (p = 0.122) between this group and patients with a positive scan, but there was a significant difference in PSA (p = 0.028), T stage (p = 0.006) and Gleason score (p = 0.023). In comparison with BS, AS‐MRI detection rate was equivalent or higher compared with the literature. Based on NHS tariff calculations, there would be a minimum cost saving of £8406.89. All patients underwent AS‐MRI within 14 days. CONCLUSION: The use of AS‐MRI to stage BM in high‐risk PCa is both feasible and results in a reduced burden of expenditure. John Wiley and Sons Inc. 2023-01-31 /pmc/articles/PMC10071081/ /pubmed/37025475 http://dx.doi.org/10.1002/bco2.210 Text en © 2023 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles El‐Taji, Omar Evans, Hannah Arora, Vandan Amin, Suzanne Kumar, Manal Rajan, Thiagarajan Nambi Diagnostic and cost‐effectiveness of axial skeleton MRI in staging high‐risk prostate cancer |
title | Diagnostic and cost‐effectiveness of axial skeleton MRI in staging high‐risk prostate cancer |
title_full | Diagnostic and cost‐effectiveness of axial skeleton MRI in staging high‐risk prostate cancer |
title_fullStr | Diagnostic and cost‐effectiveness of axial skeleton MRI in staging high‐risk prostate cancer |
title_full_unstemmed | Diagnostic and cost‐effectiveness of axial skeleton MRI in staging high‐risk prostate cancer |
title_short | Diagnostic and cost‐effectiveness of axial skeleton MRI in staging high‐risk prostate cancer |
title_sort | diagnostic and cost‐effectiveness of axial skeleton mri in staging high‐risk prostate cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071081/ https://www.ncbi.nlm.nih.gov/pubmed/37025475 http://dx.doi.org/10.1002/bco2.210 |
work_keys_str_mv | AT eltajiomar diagnosticandcosteffectivenessofaxialskeletonmriinstaginghighriskprostatecancer AT evanshannah diagnosticandcosteffectivenessofaxialskeletonmriinstaginghighriskprostatecancer AT aroravandan diagnosticandcosteffectivenessofaxialskeletonmriinstaginghighriskprostatecancer AT aminsuzanne diagnosticandcosteffectivenessofaxialskeletonmriinstaginghighriskprostatecancer AT kumarmanal diagnosticandcosteffectivenessofaxialskeletonmriinstaginghighriskprostatecancer AT rajanthiagarajannambi diagnosticandcosteffectivenessofaxialskeletonmriinstaginghighriskprostatecancer |